This study focuses on adults with *metastatic colorectal cancer (mCRC)*, which means the cancer has spread beyond their colon. Participants must have tried standard treatments without success. They will receive a treatment combination of three drugs: **irinotecan** (given through a vein), **TAS-102** (taken orally), and **bevacizumab** (given through a vein). The treatment cycle repeats every 14 days.
Key points:
- Each treatment cycle lasts 14 days.
- Regular imaging tests will check if the cancer is shrinking.
- Participants need to be between 18 and 70 years old and in good physical health.
The study wants to learn how well this drug combination works and how safe it is for patients. Participants must meet specific health criteria and cannot have certain other health issues. They will need to sign a consent form to join. If you have questions about whether you qualify or what the study involves, talk to your doctor. They can help you decide if this study is right for you.